We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis Settles Gleevec Patent Suit; Generic Version Set to Launch in 2016
Novartis Settles Gleevec Patent Suit; Generic Version Set to Launch in 2016
Novartis has gained an extra seven months of marketing exclusivity on its blockbuster leukemia drug Gleevec in a settlement with Sun Pharma that permits the Indian manufacturer to launch a generic version of the drug in the U.S. as early as Feb. 1, 2016, the firms said May 15.